Copyright
©The Author(s) 2021.
World J Cardiol. Dec 26, 2021; 13(12): 710-719
Published online Dec 26, 2021. doi: 10.4330/wjc.v13.i12.710
Published online Dec 26, 2021. doi: 10.4330/wjc.v13.i12.710
Table 1 Indications and dosage of dabigatran
| Indication | Renal function | Doses |
| Non-valvular atrial fibrillation | CrCl > 30 mL/min | 150 mg BID |
| CrCl 15-30 mL/min | 75 mg BID | |
| CrCl < 15 mL/min | Avoid use | |
| Venous thromboembolism treatment | CrCl > 30 mL/min | 150 mg BID |
| CrCl < 30 mL/min | Avoid use | |
| Venous thromboembolism prophylaxis following hip/knee replacement surgery | CrCl > 30mL/min | 110 mg one dose followed by 220 mg daily |
| CrCl < 30 mL/min | Avoid use |
- Citation: Javed A, Ajmal M, Wolfson A. Dabigatran in cardiovascular disease management: A comprehensive review. World J Cardiol 2021; 13(12): 710-719
- URL: https://www.wjgnet.com/1949-8462/full/v13/i12/710.htm
- DOI: https://dx.doi.org/10.4330/wjc.v13.i12.710